selectION Therapeutics

selectION Therapeutics is pioneering a new class of autoimmune therapies with its lead candidate, si-544, a first-in-class Kv1.3 blocker. The drug has successfully completed Phase 1b proof-of-concept trials in psoriasis and atopic dermatitis, demonstrating safety, tolerability, and early efficacy signals. The company is now planning Phase 2 studies, positioning si-544 as a potential disease-modifying, systemic first-line treatment with broad applicability across over 80 T cell-mediated autoimmune indications. Backed by strong scientific rationale and a management team with industry experience, selectION is targeting a massive, underserved market dominated by non-specific immunosuppressants.

Selective pharmacological inhibition of the Kv1.3 potassium ion channel to precisely deactivate pathogenic effector memory T (TEM) cells while preserving immune competence.

The autoimmune market is dominated by broad immunosuppressants (steroids, DMARDs), biologics (TNF, IL inhibitors), and JAK inhibitors. selectION's main competitive differentiation is the precise targeting of disease-causing T cells only, aiming for a superior safety profile. It faces competition from other companies developing targeted immunomodulators, but its Kv1.3 mechanism is unique and first-in-class.